Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2011

01-08-2011 | Epidemiology

Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers

Authors: S. U. Dhar, H. P. Cooper, T. Wang, B. Parks, S. A. Staggs, S. Hilsenbeck, S. E. Plon

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Login to get access

Abstract

The National Comprehensive Cancer Network (NCCN) has published guidelines for hereditary breast and ovarian cancer syndrome (HBOCS) management. Little data exist on compliance with these guidelines among different physician specialties. We performed an on-line case-based survey by randomly sampling physicians from five specialties, Family Medicine (FM), Obstetrics and Gynecology (OG), General Surgery (GS), Internal Medicine (IM), and Hematology and Oncology (HO). The physicians (n = 225) were asked to provide HBOCS management of healthy women ages 40–42 in the presence of a familial BRCA1 mutation. For women negative for the BRCA1 mutation, 59% of the physicians recommended appropriate surveillance although with significant differences among specialties; P = 0.01. Using an aggregate screening intensity score, physicians clearly recommended more intense screening for mutation positive than negative women (P < 0.0001), but only 16% of physicians followed NCCN guidelines for BRCA1-positive women. Seventy-six percent of all physicians recommended breast MRI with significant variation among specialties ranging from 62% of FM to 89% of OG (P = 0.0020). Similarly, 63% of physicians recommended prophylactic oophorectomy, with 76 and 78% of GS and OG compared to 38% of IM (P < 0.0001) and 57% recommended prophylactic mastectomy ranging from 84% of HO to 32% of FM (P < 0.0001). Independent of specialty, respondents with BRCA testing experience recommended more intense management than those without; P = 0.021. Management recommendations of BRCA1 mutation carriers are not consistent with NCCN guidelines and vary by medical specialty and genetic testing experience. Targeted education of physicians by specialty is needed, so that optimal management is offered to these high-risk women.
Literature
1.
go back to reference Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD et al (2010) Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 8:562–594PubMed Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD et al (2010) Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 8:562–594PubMed
2.
go back to reference Burke W, Daly M, Garber J, Botkin J, Kahn MJ et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277:997–1003PubMedCrossRef Burke W, Daly M, Garber J, Botkin J, Kahn MJ et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277:997–1003PubMedCrossRef
3.
go back to reference Saslow D, Boetes C, Burke W, Harms S, Leach MO et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89PubMedCrossRef Saslow D, Boetes C, Burke W, Harms S, Leach MO et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89PubMedCrossRef
4.
go back to reference Scheuer L, Kauff N, Robson M, Kelly B, Barakat R et al (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260–1268PubMedCrossRef Scheuer L, Kauff N, Robson M, Kelly B, Barakat R et al (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260–1268PubMedCrossRef
5.
go back to reference Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van‘t Veer L et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22:1055–1062PubMedCrossRef Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van‘t Veer L et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22:1055–1062PubMedCrossRef
6.
go back to reference Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622PubMedCrossRef Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622PubMedCrossRef
7.
go back to reference Plon SE, Cooper PH, Parks B, Dhar S, Kelly A, Weinberg A, Staggs S, Wang T, Hilsenbeck S (2011) Genetic testing and cancer risk management recommendations by Physicians for at risk relatives. Genet Med 13(2):148–154PubMedCrossRef Plon SE, Cooper PH, Parks B, Dhar S, Kelly A, Weinberg A, Staggs S, Wang T, Hilsenbeck S (2011) Genetic testing and cancer risk management recommendations by Physicians for at risk relatives. Genet Med 13(2):148–154PubMedCrossRef
8.
go back to reference Doksum T, Bernhardt BA, Holtzman NA (2003) Does knowledge about the genetics of breast cancer differ between nongeneticist physicians who do or do not discuss or order BRCA testing? Genet Med 5:99–105PubMedCrossRef Doksum T, Bernhardt BA, Holtzman NA (2003) Does knowledge about the genetics of breast cancer differ between nongeneticist physicians who do or do not discuss or order BRCA testing? Genet Med 5:99–105PubMedCrossRef
9.
go back to reference Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427–437PubMedCrossRef Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427–437PubMedCrossRef
10.
go back to reference Rowley PT, Loader S (1996) Attitudes of obstetrician–gynecologists toward DNA testing for a genetic susceptibility to breast cancer. Obstet Gynecol 88:611–615PubMedCrossRef Rowley PT, Loader S (1996) Attitudes of obstetrician–gynecologists toward DNA testing for a genetic susceptibility to breast cancer. Obstet Gynecol 88:611–615PubMedCrossRef
11.
go back to reference O’Malley MS, Klabunde CN, McKinley ED, Newman B (1997) Should we test women for inherited susceptibility to breast cancer? What do NC primary care physicians think. N C Med J 58:176–180PubMed O’Malley MS, Klabunde CN, McKinley ED, Newman B (1997) Should we test women for inherited susceptibility to breast cancer? What do NC primary care physicians think. N C Med J 58:176–180PubMed
12.
go back to reference Cho MK, Sankar P, Wolpe PR, Godmilow L (1999) Commercialization of BRCA1/2 testing: practitioner awareness and use of a new genetic test. Am J Med Genet 83:157–163PubMedCrossRef Cho MK, Sankar P, Wolpe PR, Godmilow L (1999) Commercialization of BRCA1/2 testing: practitioner awareness and use of a new genetic test. Am J Med Genet 83:157–163PubMedCrossRef
13.
go back to reference Polednak AP (1998) Do physicians discuss genetic testing with family-history-positive breast cancer patients? Conn Med 62:3–7PubMed Polednak AP (1998) Do physicians discuss genetic testing with family-history-positive breast cancer patients? Conn Med 62:3–7PubMed
14.
go back to reference Wilkins-Haug L, Hill LD, Power ML, Holzman GB, Schulkin J (2000) Gynecologists’ training, knowledge, and experiences in genetics: a survey. Obstet Gynecol 95:421–424PubMedCrossRef Wilkins-Haug L, Hill LD, Power ML, Holzman GB, Schulkin J (2000) Gynecologists’ training, knowledge, and experiences in genetics: a survey. Obstet Gynecol 95:421–424PubMedCrossRef
15.
go back to reference Julian-Reynier C, Eisinger F, Moatti JP, Sobol H (2000) Physicians’ attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines. Eur J Hum Genet 8:204–208PubMedCrossRef Julian-Reynier C, Eisinger F, Moatti JP, Sobol H (2000) Physicians’ attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines. Eur J Hum Genet 8:204–208PubMedCrossRef
16.
go back to reference Houn F, Helzlsouer KJ, Friedman NB, Stefanek ME (1995) The practice of prophylactic mastectomy: a survey of Maryland surgeons. Am J Public Health 85:801–805PubMedCrossRef Houn F, Helzlsouer KJ, Friedman NB, Stefanek ME (1995) The practice of prophylactic mastectomy: a survey of Maryland surgeons. Am J Public Health 85:801–805PubMedCrossRef
17.
go back to reference Eisinger F, Stoppa-Lyonnet D, Lasset C, Vennin P, Chabal F et al (2001) Comparison of physicians’ and cancer prone women’s attitudes about breast/ovarian prophylactic surgery. Results from two national surveys. Fam Cancer 1:157–162PubMedCrossRef Eisinger F, Stoppa-Lyonnet D, Lasset C, Vennin P, Chabal F et al (2001) Comparison of physicians’ and cancer prone women’s attitudes about breast/ovarian prophylactic surgery. Results from two national surveys. Fam Cancer 1:157–162PubMedCrossRef
18.
go back to reference Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C et al (2008) Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 26:1093–1097PubMedCrossRef Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C et al (2008) Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 26:1093–1097PubMedCrossRef
19.
go back to reference Patani N, Mokbel K (2008) The utility of MRI for the screening and staging of breast cancer. Int J Clin Pract 62:450–453PubMedCrossRef Patani N, Mokbel K (2008) The utility of MRI for the screening and staging of breast cancer. Int J Clin Pract 62:450–453PubMedCrossRef
20.
go back to reference Granader EJ, Dwamena B, Carlos RC (2008) MRI and mammography surveillance of women at increased risk for breast cancer: recommendations using an evidence-based approach. Acad Radiol 15:1590–1595PubMedCrossRef Granader EJ, Dwamena B, Carlos RC (2008) MRI and mammography surveillance of women at increased risk for breast cancer: recommendations using an evidence-based approach. Acad Radiol 15:1590–1595PubMedCrossRef
21.
go back to reference Hunter A, Wright P, Cappelli M, Kasaboski A, Surh L (1998) Physician knowledge and attitudes towards molecular genetic (DNA) testing of their patients. Clin Genet 53:447–455PubMedCrossRef Hunter A, Wright P, Cappelli M, Kasaboski A, Surh L (1998) Physician knowledge and attitudes towards molecular genetic (DNA) testing of their patients. Clin Genet 53:447–455PubMedCrossRef
22.
go back to reference Wideroff L, Vadaparampil ST, Greene MH, Taplin S, Olson L et al (2005) Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet 42:749–755PubMedCrossRef Wideroff L, Vadaparampil ST, Greene MH, Taplin S, Olson L et al (2005) Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet 42:749–755PubMedCrossRef
23.
go back to reference Loescher LJ, Lim KH, Leitner O, Ray J, D’Souza J et al (2009) Cancer surveillance behaviors in women presenting for clinical BRCA genetic susceptibility testing. Oncol Nurs Forum 36:E57–E67PubMedCrossRef Loescher LJ, Lim KH, Leitner O, Ray J, D’Souza J et al (2009) Cancer surveillance behaviors in women presenting for clinical BRCA genetic susceptibility testing. Oncol Nurs Forum 36:E57–E67PubMedCrossRef
24.
go back to reference Carroll JC, Brown JB, Blaine S, Glendon G, Pugh P et al (2003) Genetic susceptibility to cancer. Family physicians’ experience. Can Fam Physician 49:45–52PubMed Carroll JC, Brown JB, Blaine S, Glendon G, Pugh P et al (2003) Genetic susceptibility to cancer. Family physicians’ experience. Can Fam Physician 49:45–52PubMed
25.
go back to reference Watson EK, Shickle D, Qureshi N, Emery J, Austoker J (1999) The ‘new genetics’ and primary care: GPs’ views on their role and their educational needs. Fam Pract 16:420–425PubMedCrossRef Watson EK, Shickle D, Qureshi N, Emery J, Austoker J (1999) The ‘new genetics’ and primary care: GPs’ views on their role and their educational needs. Fam Pract 16:420–425PubMedCrossRef
Metadata
Title
Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers
Authors
S. U. Dhar
H. P. Cooper
T. Wang
B. Parks
S. A. Staggs
S. Hilsenbeck
S. E. Plon
Publication date
01-08-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1449-7

Other articles of this Issue 1/2011

Breast Cancer Research and Treatment 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine